Kornimate/medical-research-clean huggingface dataset:
data analysis for drug repurposing for effective alzheimer's medicines - (dream) probenecid vs allopurinol

Conditions: Gout

Summary: this study aims to evaluate the comparative risk of dementia/alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.

this is a non-randomized, non-interventional study that is part of the dream study of brigham and women's hospital. dream is led by dr. madhav thambisetty, md, phd, chief of the clinical and translational neuroscience section, laboratory of behavioral neuroscience, national institute on aging (nia) intramural research program. this study aims to evaluate the comparative risk of dementia/alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication using healthcare claims data.

Eligibility criteria:
please see https://docs.google.com/spreadsheets/d/1n3ivoirgdws7oikiowwgphhgssxx7swdihpeez-ft7c/edit?usp=sharing or appendix a for full code and algorithm definitions. medicare timeframe: 2007 to 2017 (end of data availability). inclusion criteria: * 1. no prior use of urate-lowering agents, including probenecid and allopurinol anytime prior to cohort entry date * 2. enrollment in medicare part a, b, and d with no hmo coverage for 365 days prior to and including cohort entry date exclusion criteria: * 1. prior history of dementia measured anytime prior to cohort entry date * 2. no prior history of gout recorded in the 365 days prior to cohort entry date * 3. prior history of nursing home admission in the 365 days prior to the cohort entry date
raftlin-1 levels in axial spondyloarthritis and psoriatic arthritis

Conditions: Axial Spondyloarthritis; Psoriatic Arthritis

Summary: unlike other rheumatic diseases, acute phase reactants such as c-reactive protein and erythrocyte sedimentation rate are not diagnostic for patients with spondyloarthropathies (spa). also, it is not possible to monitor disease activity with these tests. on the other hand, hla-b27 positivity varies between races, and 8% of the normal population is hla-b27 positive. in this manner, new biomarkers for endorsing the diagnosis and monitoring the disease activity are necessary. acute phase reactants are not sensitive for diagnosing and assessing disease activity. this may lead to a diagnostic delay of up to 9 years. the investigators hypothesize that raftlin-1, thought to have a regulatory role in th17 function and il-17-mediated immunity, may be a novel biomarker for showing inflammation-related clinical features.

unlike other rheumatic diseases, acute phase reactants such as c-reactive protein and erythrocyte sedimentation rate are not diagnostic for patients with spondyloarthropathies (spa). also, it is not possible to monitor disease activity with these tests. on the other hand, hla-b27 positivity varies between races, and 8% of the normal population is hla-b27 positive. in this manner, new biomarkers for endorsing the diagnosis and monitoring the disease activity are necessary. in recent years raftlin, a significant lipid raft protein responsible for transmembrane signal transmission, was found. it has been discovered that the raftlin protein has two subtypes (raftlin-1 and raftlin-2), and in transgenic mice without raftlin genes, t-cell-dependent immunity has been altered. cytokine production, especially il-17, is diminished in t cells with the lack of raftlin protein, while it is increased in t cells, including transgenic raftlin. this condition is associated with tcr-related signaling pathways. particularly, lck protein occurrence in lipid raft is increased with raftlin overexpression, while it is diminished with absence. regarding this, raftlin is thought to modulate tcr signaling, thus altering the t-cell mediated immunity. acute phase reactants are not sensitive for diagnosing and assessing disease activity. this may lead to a diagnostic delay of up to 9 years. the investigators hypothesize that raftlin-1, thought to have a regulatory role in th17 function and il-17-mediated immunity, may be a novel biomarker for showing inflammation-related clinical features.

Eligibility criteria:
inclusion criteria: * being aged 18 to 65 * meeting asas axial spondyloarthritis classification criteria * meeting the caspar (classification criteria for psoriatic arthritis) criteria exclusion criteria: * having a burn or a wound * active infection * systemic inflammatory disease (type 1 dm, autoimmune thyroiditis, other inflammatory rheumatic conditions etc.) * pregnancy * malignancy * severe cognitive function disorder

Keywords: axial spondyloarthritis psoriatic arthritis raftlin-1
pain classification in caregivers for children with cerebral palsy

Conditions: Chronic Pain; Cerebral Palsy; Musculoskeletal Pain; Caregivers

Summary: the care of children with cerebral palsy is a process that continues for many years. individuals who take care of them experience musculoskeletal pain due to the difficulties they experience and face pain that becomes chronic over time. for individuals who take care of children with cp, determining the types of chronic pain is important in order to clarify the classification criteria and for individuals to reach better living standards by tailoring the treatments they will receive. therefore, the aim of the study is to determine the types of chronic pain in caregivers for children with cerebral palsy.


Eligibility criteria:
inclusion criteria: * having musculoskeletal pain complaints for the last 6 months or more * experienced musculoskeletal pain or a sensitive disorder (like numbness, tingling, etc.) anywhere in body for which they stated a minimum score of 2 on a numeric pain rating scale * pain that lasts at least 6 months * to provide the documented diagnosis of cerebral palsy of the child in the care of the participants. exclusion criteria: * having severe psychological illness * having a cognitive dysfunction * not participating in the assessment or submitting incomplete answers for questionnaires

Keywords: chronic pain
ai-based upper limb rehabilitation therapy with motore

Conditions: Stroke

Summary: stroke is a common disease with a high disabling impact; it is the world's second leading cause of death and the third leading cause of disability. robotic therapy has been proposed as a viable approach for the rehabilitation of the upper limb, as a way to increase the amount and the intensity of the therapy, and to standardize the treatment. however, robotic technologies have not yet been used to their full potential in terms of tailoring rehabilitation paths and monitoring the response to treatments. the main goal of the study is to use ai algorithms to (a) predict the recovery of the patients and (b) suggest exercises and parameters to improve the outcomes of the treatment.


Eligibility criteria:
inclusion criteria: * first ischemic or hemorrhagic stroke (verified by mri or ct); * time since stroke onset between 1 and 6 months (subacute phase) * cognitive abilities adequate to understand the experiments and the follow instructions * upper limb impairment (fugl-meyer assessment - upper extremity score ≤58); exclusion criteria: * fixed contractions in the affected limb (ankylosis, modified ashworth scale equal to 4); * inability to understand the instructions required for the study; * behavioral disorders that may influence therapeutic activity; * other orthopedic or neurological diseases * inability or unwillingness to provide informed consent.
an intervention to improve hiv pre-exposure prophylaxis initiation, adherence and linkage to care for recently incarcerated men who inject drugs.

Conditions: Hiv; Substance Use Disorders

Summary: pre-exposure prophylaxis (prep) is effective in preventing hiv infection among people who inject drugs (pwid) yet studies suggest that its use is low among this population which is particularly vulnerable to hiv infection. the criminal justice (cj) system, at the intersection of increased risk of hiv infection and substance use, presents a unique opportunity to engage pwid in hiv prevention care that incudes prep. the study will characterize the facilitators and barriers to prep initiation, adherence and linkage to care among male pwid that are experiencing incarceration and develop the "prepare-for-release" intervention to promote prep initiation, adherence and linkage to care upon release from incarceration into the community.


Eligibility criteria:
inclusion criteria: * at least 18 years of age * incarcerated at the rhode island department of corrections * identifies as male * reports a history of injection drug use * meets cdc clinical criteria for prep use * able to provide written and verbal consent in either english or spanish exclusion criteria: * unable to provide written and/or verbal consent

Keywords: hiv substance use disorders injection drug use incarceration
ferinject® assessment in gastrectomy patients with acute isovolemic anemia (fairy)

Conditions: Anemia

Summary: this study is designed to evaluate the efficacy of ferinject® in improving acute isovolemic anemia after gastrectomy for gastric cancer in terms of quality of life(qol )and objective measures (hb and iron parameters). furthermore, the tolerability and safety of ferinject® treatment will be evaluated.

randomized patient-blind placebo controlled study. hb level of 10 g/dl will be used as a cut-off value for our study based on the guidelines published by american society of clinical oncology and the american society of hematology for the treatment of cancer-related anemia, recommending hb\<10 g/dl as a treatment threshold. ferinject® to be administered based on hb and body weight per approved summary of product characteristics (smpc). 5 - 7 days after gastrectomy for gastric cancer, consented patients with 7g/dl≤hb\<10g/dl will be administered ferinject® or placebo (normal saline) based on the results of randomization. • study group ferinject®to be administered as iv drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 kg or 6 minutes (for 500mg single administration) for body weight \<50kg . note, ferinject® should be administered to a maximum of 20mg iron/kg. therefore in patients with a body weight \<50kg, administration of ferinject® should be limited to 500mg at baseline . all patients with a serum ferritin value \<15ng/ml at week 4 visit that a second dose (of 500mg iron or equivalent placebo) will be given.(study group: ferinject®500mg, control group:placebo) • control group placebo will be in the form of normal saline administered over same time period as equivalent ferinject® administration. iv drip infusion or undiluted bolus injection with a minimum administration time of 15 minutes (200ml as infusion or 20ml as bolus injection) for body weight ≥50 kg or 6 minutes (100ml normal as infusion or 10ml as bolus injection) for body weight \<50 kg.

Eligibility criteria:
inclusion criteria: * ≥ 20 years old * 7g/dl ≤ hb \< 10g/dl at 5 - 7 days after gastrectomy for gastric cancer * signed written informed consent exclusion criteria: * a concurrent medical condition(s) that would prevent compliance or participation or jeopardize the health of the patient * hypersensitivity to any component of the formulation * active severe infection/inflammation * history of transfusion, erythropoietin, \> 500 mg intravenous iron administration within 4 weeks prior to screening. * history of acquired iron overload. * pregnancy or lactation. * decreased renal function (defined as creatinine clearance \< 50 ml/min calculated by cockcroft-gault) * chronic liver disease or increase of liver enzymes (alt, ast) \> 3 times the upper limit of normal range. * participation in any other interventional study within 1 month prior to screening.

Keywords: acute isovolemic anemia after gastrectomy for gastric cancer
the neuroprotection of remote ischemic preconditioning (ripc) on cardiac surgery in multicenter

Conditions: Cardiac Surgery Patients

Summary: the current study is designed to clarify the neuroprotective effect of remote ischemic preconditioning on the patients underwent open-heart cardiac surgery.

background: brain ischemia and injury are commonly contributed to perioperative morbidity and mortality after cardiac surgery. remote ischemic preconditioning (ripc) is a phenomenon whereby brief periods of ischemia followed by reperfusion in one organ provide systemic protection from prolonged ischemia. to investigate whether remote preconditioning protects the brain injury in patients undergoing elective cardiac surgery, a randomized trial will be performed in current study. designing 150 patients will be randomize assigned to cardiac surgery with ripc or without ripc (control). remote ischemic preconditioning consist of three 5-min cycles of right upper limb ischaemia, induced by an automated cuff-inflator placed on the upper arm and inflated to 200 mm hg, with an intervening 5 min of reperfusion during which the cuff is deflated. cerebral injury was assessed by s-100b, nse, and neurological function scores in different time points. expected results ripc will reduce the incidence of cerebral injury in cardiac surgery. conclusions: in patients undergoing elective cardiac surgery, ripc reduces the incidence of postoperative cerebral injury.

Eligibility criteria:
inclusion criteria: * patients diagnosed with acquired heart valve diseases scheduled for valve replacement or cabg exclusion criteria: * were unable to give informed consent * patients who presented with other systemic diseases such as hepatic,renal, and pulmonary diseases, or have had a heart operation before, were excluded. * additionally, patients taking antidiabetic sulfonylurea or glibenclamide were excluded because these agents have been shown to abrogate the cardioprotection elicited by ischemic preconditioning.

Keywords: cardiac surgery ripc brain injury
tampostat for management of postpartum hemorrhage

Conditions: Postpartum Hemorrhage

Summary: the purpose of the study is to evaluate the safety, feasibility and applicability of a new device 'tampostat' in the management of primary postpartum hemorrhage and compare the efficacy of 'tampostat' in terms of arresting primary pph with that of the conventional condom catheter.

this will be a 2-year study having two parts. part a will be a proof of concept (poc) study that will be conducted at the obstetrical ward of shaheed suhrawardi medical college hospital (shsmch) and dhaka medical college hospital (dmch). there is no sample size estimation of this poc study that will assess safety, feasibility and applicability of using tampostat on 5 consenting women with pph for each hospital. part b of the study will be an open label, randomized clinical trial that will be conducted at the obstetrical ward of dhaka medical college hospital (dmch). in this part, 344 consenting women with primary pph will be enrolled, and allocated to either tampostat or the control intervention in equal numbers per randomization (172 patients in each arm). in both these parts, tampostat will be used only when active management of third stage of labour (amtsl) has failed to prevent pph within 24 hours after delivery. all the doctors involved in the provision of care and treatment to pph patients will be trained on the who's standard of care; they will also receive training on appropriate use of the devices to be used in this trial. an expert committee constituted of obgyn professionals, clinical trial specialists, and statisticians will oversee the technical management of patients, data collection and their procedures, and ethical issues in this trial.

Eligibility criteria:
inclusion criteria: 1. women who delivered their baby at the site hospital, or attended the site hospital with pph that started within the last 24 hours. 2. women with primary pph have received amtsl. 3. pph is due to atonic uterus. 4. provides written informed consent for enrolment in the study. exclusion criteria: 1. primary pph caused by retained placenta or ruptured uterus. 2. women who delivered before 28 weeks of gestation. 3. women not willing to participate in the study.

Keywords: tampostat tamponade postpartum hemorrhage
assessment of patient satisfaction after arthroplasty: a comparative study by implant type

Conditions: Gonarthrosis

Summary: the main objective of this study is to evaluate the benefit of personalized prostheses compared to conventional prostheses on patient satisfaction 24 months after total knee arthroplasty.

prospective randomized monocentric prospective comparative study carried out as a single blind study on two parallel groups (standard implant or customized implant). secondary objectives: compare between groups : * the functional outcome of the arthroplasty * pain progression * the evolution of the quality of life * the conditions of the surgery (duration of surgery, length of hospitalization, blood loss) * the frequency of adverse events related to arthroplasty

Eligibility criteria:
inclusion criteria: * adult man or woman who has signed consent to participate in the study * patient with uni- or bilateral primary gonarthrosis * for which an indication for total knee arthroplasty has been established exclusion criteria: * history of knee arthroplasty or osteotomy * history of knee fracture * inflammatory rheumatic disease or any other progressive concomitant disease that may affect the patient's functional prognosis. * joint or extra-articular deformities of the lower limb of traumatic origin * neurological diseases, stroke sequelae * mental disability or any other reason that may hinder the understanding or strict application of the protocol * patient not affiliated to the french social security scheme * patient under legal protection, guardianship or trusteeship * patient already included in another therapeutic study protocol or having participated in another trial within the previous three months * arthroplasty actually performed * absence of per operative complications in bone (femoral or tibial bone), ligament (rupture or disinsertion of the patellar or quadricipital tendon) or nerve (lesion of the external popliteal sciatica).
laser acupuncture in rheumatoid arthritis geriatric patients

Conditions: Rheumatoid Arthritis

Summary: studying the effect of laser acupuncture on geriatric patients with rheumatoid arthritis


Eligibility criteria:
inclusion criteria: * patients referred from physician (immunologist) diagnosed with rheumatoid arthritis. exclusion criteria: * patients having the disease overlapping with other connective tissue diseases, such as systematic lupus erythromatosus and systematic sclerosis. * history of malignancies.
the cognitive and sport virtual epic training study for cardiovascular diseases

Conditions: Cardiovascular Diseases

Summary: covepicardio trial is designed to document the effects of remote monitoring of physical exercise and home-based cognitive training on cognitive and physical functions in older adults with cardiovascular diseases.

cardiac rehabilitation is a class i level a recommendation with clinical benefits that are now well documented. due to the covid-19 pandemic, accessibility to rehabilitation services and exercise training programs are limited. quarantine measures can induce collateral damages to cardiovascular and psychological health, in particular in clinical population. cardiovascular diseases (cvd) are associated with cognitive deficits and increased risk of dementia later in life. specifically for cvd, physical inactivity and excessive sedentary lifestyle induced by confinement decrease cardiorespiratory capacity, increase the risk of acute events and rehospitalization. maintaining a minimum of physical activity during a health crisis is fundamental. in this context, our team has developed an innovative program of exercise and cognitive training at home. considering the added benefits of combining cognitive training to physical exercise to further enhance health and cognition in seniors with cvd, this project also addresses the added benefits of a multidomain intervention combining a home-based physical exercise intervention with a cognitive training.

Eligibility criteria:
inclusion criteria: * adults aged 50 and older * have access to internet * have access to a tablet (i.e., ipad or android) or a computer * diagnostic of cardiovascular disease (stable chronic systolic or diastolic heart failure, atrial fibrillation, documented atherosclerotic disease). * able to do light to moderate aerobic exercice training * with no contraindication to exercise training exclusion criteria: * non-cardiopulmonary limitation to exercise (e.g., arthritis) * severe exercise intolerance * respiratory disease (e.g., asthma, copd, covid-19) * mini mental scale examination (mmse) telephone version lower than 19/23

Keywords: cardiovascular diseases home-based exercise training cognitive training covid-19 rehabilitation cognition
pattern recognition prosthetic control

Conditions: Prosthesis User; Congenital Amputation of Upper Limb; Amputation; Traumatic, Limb

Summary: many different factors can degrade the performance of an upper limb prosthesis users control with electromyographic (emg)-based pattern recognition control. conventional control systems require frequent recalibration in order to achieve consistent performance which can lead to prosthetic users choosing to wear their device less. this study investigates a new adaptive pattern recognition control algorithm that retrains, rather than overwrite, the existing control system each instance users recalibrate. the study hypothesis is that such adaptive control system will lead to more satisfactory prosthesis control thus reducing the need for recalibration and increasing how often users wear their device. participants will wear their prosthesis as they would normally at-home using each control system (adaptive and non-adaptive) for an 8-week period with an intermittent 1-week washout period (17 weeks total). prosthetic usage will be monitored during each period in order to compare user wear time and recalibration frequency when using adaptive or non-adaptive control. participants will also play a set of virtual games on a computer at the start (0-months), mid-point (1-months) and end (2-months) of each period that will test their ability to control prosthesis movement using each control system. changes in user performance will be evaluated during each period and compared between the two control systems. this study will not only evaluate the effectiveness of adaptive pattern recognition control, but it will be done at-home under typical and realistic prosthetic use conditions.


Eligibility criteria:
inclusion criteria: * subjects have an upper-limb difference (congenital or acquired) at the transradial (between the wrist and elbow), elbow disarticulation (at the elbow), transhumeral (between the elbow and shoulder), or shoulder disarticulation (at the shoulder) level. * subjects are suitable to be, or already are, a coapt pattern recognition user (coapt complete control gen 2). * subjects are between the ages of 18 and 70. exclusion criteria: * subjects with significant cognitive deficits or visual impairment that would preclude them from giving informed consent or following instructions during the experiments, or the ability to obtain relevant user feedback discussion. * subjects who are non-english speaking. * subjects who are pregnant.

Keywords: pattern recognition home trial randomized cross-over trial prosthesis electromyography